NASDAQ:KERX - Keryx Biopharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.29 +0.14 (+4.44 %)
(As of 12/11/2018 01:24 AM ET)
Previous Close$3.15
Today's Range$3.12 - $3.30
52-Week Range$2.47 - $5.98
Volume1.19 million shs
Average Volume1.15 million shs
Market Capitalization$322.48 million
P/E Ratio-3.74
Dividend YieldN/A
Beta2.35
Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

Receive KERX News and Ratings via Email

Sign-up to receive the latest news and ratings for KERX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:KERX
Previous Symbol
CUSIP49251510
Phone617-466-3500

Debt

Debt-to-Equity RatioN/A
Current Ratio2.21
Quick Ratio1.19

Price-To-Earnings

Trailing P/E Ratio-3.74
Forward P/E Ratio-5.58
P/E GrowthN/A

Sales & Book Value

Annual Sales$60.64 million
Price / Sales5.55
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.12) per share
Price / Book-27.42

Profitability

EPS (Most Recent Fiscal Year)($0.88)
Net Income$-163,440,000.00
Net Margins-96.41%
Return on EquityN/A
Return on Assets-60.05%

Miscellaneous

Employees210
Outstanding Shares102,380,000
Market Cap$322.48 million
OptionableOptionable

Keryx Biopharmaceuticals (NASDAQ:KERX) Frequently Asked Questions

What is Keryx Biopharmaceuticals' stock symbol?

Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."

How were Keryx Biopharmaceuticals' earnings last quarter?

Keryx Biopharmaceuticals (NASDAQ:KERX) posted its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The biopharmaceutical company had revenue of $28.04 million for the quarter, compared to the consensus estimate of $29.56 million. View Keryx Biopharmaceuticals' Earnings History.

When is Keryx Biopharmaceuticals' next earnings date?

Keryx Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Keryx Biopharmaceuticals.

What price target have analysts set for KERX?

6 analysts have issued 1-year target prices for Keryx Biopharmaceuticals' shares. Their predictions range from $4.00 to $9.00. On average, they expect Keryx Biopharmaceuticals' stock price to reach $6.60 in the next twelve months. This suggests a possible upside of 100.6% from the stock's current price. View Analyst Price Targets for Keryx Biopharmaceuticals.

What is the consensus analysts' recommendation for Keryx Biopharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Keryx Biopharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Keryx Biopharmaceuticals.

What are Wall Street analysts saying about Keryx Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "Valuation compelling. Keryx stock price has pulled back since the merger was announced in June, losing 33% of its value versus the XBI Biotech index losing only 9%. However we see only improving fundamentals as Auryxia revenues continue to improve QoQ." (11/9/2018)
  • 2. Maxim Group analysts commented, "Keryx reported 3Q18 with total revenue of $28.0M, a slight miss from the consensus estimate of $29.1M. US Auryxia sales for the quarter were $26.6M up 11% q/q, driven by increased RX volume. The company reported a net loss of ($17.0M) and ended the quarter with $41.1M in cash." (11/9/2018)
  • 3. According to Zacks Investment Research, "Keryx is completely dependent on Auryxia for growth as it is the only approved product in the company’s portfolio. Auryxia faces stiff competition in the United States from existing players. Shares of the company have underperformed the industry so far this year.  However, Keryx's launch of Auryxia for the second indication — iron deficiency anemia (IDA) in chronic kidney disease patients — is boosting sales of the company, given that the IDA market holds great potential. Keryx entered a definitive merger agreement with Akebia Therapeutics that will create a fully integrated company focused on the development and commercialization of therapeutics for patients with chronic kidney diseases. The combined company will be well positioned to create significant shareholder value and accelerate growth beyond what either company would achieve separately. Loss estimates have remained stable ahead of Q3 earnings release." (10/9/2018)

Has Keryx Biopharmaceuticals been receiving favorable news coverage?

News headlines about KERX stock have been trending negative on Tuesday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Keryx Biopharmaceuticals earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next few days.

Who are some of Keryx Biopharmaceuticals' key competitors?

Who are Keryx Biopharmaceuticals' key executives?

Keryx Biopharmaceuticals' management team includes the folowing people:
  • Ms. Jodie Pope Morrison, Interim CEO & Director (Age 43)
  • Mr. Scott A. Holmes, CFO, Sr. VP & Treasurer (Age 44)
  • Ms. Christine A. Carberry, Sr. VP & COO (Age 57)
  • Dr. John F. Neylan, Sr. VP & Chief Medical Officer (Age 65)
  • Mr. Tony Chambers, VP of Sales

Who are Keryx Biopharmaceuticals' major shareholders?

Keryx Biopharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Abrams Capital Management L.P. (7.57%), Vanguard Group Inc. (8.05%), BlackRock Inc. (5.98%), Rice Hall James & Associates LLC (1.85%), Bank of New York Mellon Corp (0.82%) and FMR LLC (0.48%). Company insiders that own Keryx Biopharmaceuticals stock include Brian Adams, Christine A Carberry, Greg Madison, John F Neylan, Kevin J Cameron, Scott A Holmes and Steven C Gilman. View Institutional Ownership Trends for Keryx Biopharmaceuticals.

Which institutional investors are selling Keryx Biopharmaceuticals stock?

KERX stock was sold by a variety of institutional investors in the last quarter, including Abrams Capital Management L.P., Morgan Stanley, Bristol Advisors LLC, Bank of New York Mellon Corp, Rice Hall James & Associates LLC, Lincoln Capital Corp and Credit Suisse AG. Company insiders that have sold Keryx Biopharmaceuticals company stock in the last year include Brian Adams, Christine A Carberry, Greg Madison, John F Neylan, Kevin J Cameron, Scott A Holmes and Steven C Gilman. View Insider Buying and Selling for Keryx Biopharmaceuticals.

Which institutional investors are buying Keryx Biopharmaceuticals stock?

KERX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Nexthera Capital LP, Rubric Capital Management LP, Vanguard Group Inc. and Marshall Wace LLP. View Insider Buying and Selling for Keryx Biopharmaceuticals.

How do I buy shares of Keryx Biopharmaceuticals?

Shares of KERX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Keryx Biopharmaceuticals' stock price today?

One share of KERX stock can currently be purchased for approximately $3.29.

How big of a company is Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals has a market capitalization of $322.48 million and generates $60.64 million in revenue each year. The biopharmaceutical company earns $-163,440,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Keryx Biopharmaceuticals employs 210 workers across the globe.

What is Keryx Biopharmaceuticals' official website?

The official website for Keryx Biopharmaceuticals is http://www.keryx.com.

How can I contact Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals' mailing address is ONE MARINA PARK DR., BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 617-466-3500 or via email at [email protected]


MarketBeat Community Rating for Keryx Biopharmaceuticals (NASDAQ KERX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  464 (Vote Outperform)
Underperform Votes:  321 (Vote Underperform)
Total Votes:  785
MarketBeat's community ratings are surveys of what our community members think about Keryx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe KERX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KERX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel